Surrozen to Present at Upcoming Healthcare Investor Conference
Surrozen (Nasdaq: SRZN), a biotechnology company focused on developing targeted therapeutics for severe eye diseases through Wnt pathway modulation, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
The presentation is scheduled for September 10, 2025, from 8:30 AM to 9:00 AM Pacific Time (11:30 AM to 12:00 PM Eastern Time). Investors can access the audio webcast through Surrozen's investor relations website, with a replay available afterward.
Surrozen (Nasdaq: SRZN), una societ脿 biotecnologica che sviluppa terapie mirate per gravi malattie oculari attraverso la modulazione della via Wnt, annuncia la sua partecipazione al 27掳 Annual Global Investment Conference di H.C. Wainwright.
La presentazione 猫 prevista per il 10 settembre 2025, dalle 8:30 alle 9:00 PT (dalle 11:30 alle 12:00 ET
Surrozen (Nasdaq: SRZN), una compa帽铆a biotecnol贸gica centrada en desarrollar terapias dirigidas para enfermedades oculares graves mediante la modulaci贸n de la v铆a Wnt, ha anunciado su participaci贸n en la 27.陋 Conferencia Anual Global de Inversi贸n de H.C. Wainwright.
La presentaci贸n est谩 programada para el 10 de septiembre de 2025, de 8:30 a 9:00 AM hora del Pac铆fico (de 11:30 AM a 12:00 PM hora del Este
Surrozen (Nasdaq: SRZN)鞚� Wnt 瓴诫 臁办爤鞚� 韱淀暣 欷戩 鞎堦臣 歆堩櫂鞚� 瓴儱頃� 旃橂鞝滊ゼ 臧滊皽頃橂姅 靸濍獏瓿淀暀 旮办梾鞙茧, 雼り皜鞓る姅 H.C. Wainwright 鞝�27須� 鞐半 旮�搿滊矊 韴瀽 旎嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
氚滍憸电� 2025雲� 9鞗� 10鞚� 鞓れ爠 8:30攵�韯� 9:00(韮滍弶鞏� 響滌鞁�) (霃欕秬 響滌鞁� 鞓れ爠 11:30攵�韯� 12:00)鞐� 鞓堨爼霅橃柎 鞛堨姷雼堧嫟. 韴瀽鞛愲摛鞚� Surrozen鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 鞓る敂鞓� 鞗轨簮鞀ろ姼鞐� 鞝戩啀頃� 靾� 鞛堨溂氅�, 鞚错泟 鞛箔旆�(毽攲霠堨澊)霃� 鞝滉车霅� 鞓堨爼鞛呺媹雼�.
Surrozen (Nasdaq: SRZN), une soci茅t茅 de biotechnologie ax茅e sur le d茅veloppement de th茅rapies cibl茅es pour les graves affections oculaires par modulation de la voie Wnt, a annonc茅 sa participation 脿 la 27e Conf茅rence annuelle mondiale sur l'investissement de H.C. Wainwright.
La pr茅sentation est pr茅vue le 10 septembre 2025, de 8h30 脿 9h00 (heure du Pacifique) (de 11h30 脿 12h00, heure de l'Est). Les investisseurs pourront acc茅der au webdiffusion audio via le site des relations investisseurs de Surrozen; un replay sera disponible par la suite.
Surrozen (Nasdaq: SRZN), ein Biotechnologieunternehmen, das sich auf die Entwicklung gezielter Therapien f眉r schwere Augenerkrankungen durch Modulation des Wnt-Signalwegs konzentriert, hat seine Teilnahme an der bevorstehenden H.C. Wainwright 27. Annual Global Investment Conference 补苍驳别办眉苍诲颈驳迟.
Die Pr盲sentation ist f眉r den 10. September 2025 von 8:30 bis 9:00 Uhr Pacific Time (von 11:30 bis 12:00 Uhr Eastern Time) angesetzt. Investoren k枚nnen das Audio-Webcast 眉ber die Investor-Relations-Website von Surrozen abrufen; eine Wiedergabe wird im Anschluss verf眉gbar sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (鈥淪urrozen鈥� or the 鈥淐ompany鈥�) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases,听today announced that Company management will present at an upcoming healthcare investor conference.
H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025
Surrozen presentation will be from 8:30 鈥� 9:00 AM Pacific Time/11:30 鈥�12N Eastern Time
Interested parties may access the audio webcast for the conference via the Investors section of the Surrozen website at . A replay of the webcast will be archived on the website at .
About Surrozen听
Surrozen is a biotechnology company developing tissue-specific antibodies to selectively modulate the Wnt pathway, with a current focus on ophthalmology. Its proprietary technologies aim to harness the body鈥檚 biological repair mechanisms to treat severe diseases. For more information, please visit .听听听
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as 鈥渨ill,鈥� 鈥減lan,鈥� 鈥渋ntend,鈥� 鈥減otential,鈥� 鈥渆xpect,鈥� 鈥渃ould,鈥� or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen鈥檚 discovery, research and development activities, in particular its development plans for its product candidates (including anticipated clinical development plans and timelines, the availability of data, the potential for such product candidates to be used to treat human disease or address unmet needs in serious eye diseases, as well as the potential benefits and potential differentiation from existing therapies of such product candidates). These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical and clinical trials with respect to its product candidates and potential future drug candidates; the Company鈥檚 ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen鈥檚 ability to identify, develop and commercialize drug candidates; Surrozen鈥檚 ability to successfully complete preclinical and clinical studies for its product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and all other factors discussed in Surrozen鈥檚 Annual Report on Form 10-K for the year ended December 31, 2024 filed, and Surrozen鈥檚 Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed with the Securities and Exchange Commission (鈥淪EC鈥�) under the heading 鈥淩isk Factors,鈥� and other documents Surrozen has filed, or will file, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen鈥檚 expectations, plans, or forecasts of future events and views as of the date of this press release. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen鈥檚 assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor/Media Contact:
Email:听
FAQ
When is Surrozen (SRZN) presenting at the H.C. Wainwright Conference?
How can investors access Surrozen's (SRZN) H.C. Wainwright conference presentation?
What is Surrozen's (SRZN) main business focus?
Which stock exchange is Surrozen (SRZN) listed on?
